BIIB vs MRNA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BIIB Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biogen Inc. Common Stock (BIIB) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, BIIB trades at 15.6x Forward P/E with 23.5% operating margin (+10.6% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, BIIB sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (30th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BIIB Revenue | MRNA Revenue | BIIB Op. Margin | MRNA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $13.4B | $140M | 43.8% | -306.0% | BIIB |
| FY2019 | $14.4B | $60M | 49.0% | -906.8% | BIIB |
| FY2020 | $13.4B | $800M | 33.8% | -95.0% | BIIB |
| FY2021 | $11.0B | $18.5B | 25.9% | 72.0% | MRNA |
| FY2022 | $10.2B | $19.3B | 29.9% | 48.9% | MRNA |
| FY2023 | $9.84B | $6.85B | 11.8% | -61.9% | BIIB |
| FY2024 | $9.68B | $3.24B | 16.9% | -121.9% | BIIB |
| FY2025 | $9.89B | $1.94B | 13.1% | -158.1% | BIIB |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BIIB | MRNA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $37.0B | $93.6B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | 109.9x | 23.0x | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | 15.6x | 23.0x | Lower Multiple | BIIB |
| Revenue Growth (YoY) Growth | +10.6% | +29.2% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | 23.5% | -80.8% | Higher Margin | BIIB |
| Net Profit Margin Profitability | 3.4% | -110.5% | Higher Margin | BIIB |
| Return on Equity (ROE) Capital Efficiency | 1.9% | -34.5% | Higher ROE | BIIB |
| 52-Week Range Position Momentum | 92% ($160โ$261) | 75% ($22โ$281) | Stronger Trend | BIIB |
| Beta / 30D Volatility Risk Regime | 0.27ฮฒ ยท 36% Vol | 2.35ฮฒ ยท 101% Vol | Lower Realized Risk | BIIB |
| Unified Institutional Score Composite Signal | 50.2 / 100 (HOLD) | 46.8 / 100 (HOLD) | Higher Composite | BIIB |